https://www.selleckchem.com/products/dpcpx.html
LIR-1 expanded NK cells displayed high intrinsic ADCC that, in contrast to KIR and NKG2A, was not inhibited by HLA class I. These findings identify a unique NK cell subset attractive for adoptive cell therapy to treat cancer. Given that LIR-1 binds most HLA class I molecules, this subset may be explored in both autologous and allogeneic settings to innately reject HLA class I tumor cells as well as HLA class I target cells when combined with antitumor antibodies. Further studies are warranted to address the potential of this subset . Thes
Like
Comment
Share
